<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4257525</article-id><article-id pub-id-type="pmid">25478898</article-id><article-id pub-id-type="publisher-id">PONE-D-14-19615</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0111526</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Bioenergetics</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Physical Fitness</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>The Effect of Neoadjuvant Chemoradiotherapy on Whole-Body Physical Fitness and Skeletal Muscle Mitochondrial Oxidative Phosphorylation In Vivo in Locally Advanced Rectal Cancer Patients – An Observational Pilot Study </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Mitochondrial Function after Cancer Therapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>West</surname><given-names>Malcolm A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Loughney</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lythgoe</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barben</surname><given-names>Christopher P.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Valerie L.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bimson</surname><given-names>William E.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Grocott</surname><given-names>Michael P. W.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jack</surname><given-names>Sandy</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kemp</surname><given-names>Graham J.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Colorectal Surgery Research Group, Aintree University Hospitals NHS Foundation Trust, Liverpool, United Kingdom</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Musculoskeletal Biology and MRC – Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Magnetic Resonance and Image Analysis Research Centre (MARIARC), University of Liverpool, Liverpool, United Kingdom</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Critical Care Research Area, Southampton NIHR Respiratory Biomedical Research Unit, Southampton, United Kingdom</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Anaesthesia and Critical Care Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Galgani</surname><given-names>Jose</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Pontificia Universidad Catolica de Chile, Chile</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>mwest@liverpool.ac.uk</email></corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: Professor MPW Grocott received honoraria for speaking for and/or travel expenses from: Edwards Lifescience, Fresenius-Kabi, BOC Medical (Linde Group), Ely-Lilly Critical Care, and Cortex GmBH. </plain></SENT>
<SENT sid="2" pm="."><plain>He has also received research grants from: National Institute of Health Research, Association of Anaesthetists of Great Britain and Ireland, Sir Halley Stuart Trust, Francis and Augustus Newman Foundation. </plain></SENT>
<SENT sid="3" pm="."><plain>He leads the Xtreme-Everest hypoxia research consortium, who have received un-restricted research grant funding from: BOC Medical (alinde Group) Ely-Lilly Critical Care, Smiths Medical, Deltex Medical, London Clinic, Rolex. </plain></SENT>
<SENT sid="4" pm="."><plain>Professor Grocott has received funding from commercial sources (BOC Medical [alinde Group], Ely-Lilly Critical Care, Smiths Medical, Deltex Medical, London Clinic, Rolex.), however none of this was used for this project. </plain></SENT>
<SENT sid="5" pm="."><plain>There are no other relevant declarations from any of the other authors. </plain></SENT>
<SENT sid="6" pm="."><plain>This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="7" pm="."><plain>Conceived and designed the experiments: MW VA WB MPWG SJ GJK. </plain></SENT>
<SENT sid="8" pm="."><plain>Performed the experiments: MW LL VA WB GJK. </plain></SENT>
<SENT sid="9" pm="."><plain>Analyzed the data: DL GJK MW SJ. </plain></SENT>
<SENT sid="10" pm="."><plain>Contributed reagents/materials/analysis tools: MW LL VA WB GJK. </plain></SENT>
<SENT sid="11" pm="."><plain>Wrote the paper: MW LL DL CB MPWG SJ GJK. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2014</year></pub-date><volume>9</volume><issue>12</issue><elocation-id>e111526</elocation-id><history><date date-type="received"><day>8</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 West et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>West et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title><text><SENT sid="12" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>In the United Kingdom, patients with locally advanced rectal cancer routinely receive neoadjuvant chemoradiotherapy. </plain></SENT>
<SENT sid="14" pm="."><plain>However, the effects of this on physical fitness are unclear. </plain></SENT>
<SENT sid="15" pm="."><plain>This pilot study is aimed to investigate the effect of neoadjuvant chemoradiotherapy on objectively measured in vivo muscle mitochondrial function and whole-body physical fitness. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="16" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>We prospectively studied 12 patients with rectal cancer who completed standardized neoadjuvant chemoradiotherapy, recruited from a large tertiary cancer centre, between October 2012 and July 2013. </plain></SENT>
<SENT sid="18" pm="."><plain>All patients underwent a cardiopulmonary exercise test and a phosphorus magnetic resonance spectroscopy quadriceps muscle exercise-recovery study before and after neoadjuvant chemoradiotherapy. </plain></SENT>
<SENT sid="19" pm="."><plain>Data were analysed and reported blind to patient identity and clinical course. </plain></SENT>
<SENT sid="20" pm="."><plain>Primary variables of interest were the two physical fitness measures; oxygen uptake at estimated anaerobic threshold and oxygen uptake at Peak exercise (ml.kg−1.min−1), and the post-exercise phosphocreatine recovery rate constant (min−1), a measure of muscle mitochondrial capacity in vivo. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="21" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="22" pm="."><plain>Median age was 67 years (IQR 64–75). </plain></SENT>
<SENT sid="23" pm="."><plain>Differences (95%CI) in all three primary variables were significantly negative post-NACRT: Oxygen uptake at estimated anaerobic threshold −2.4 ml.kg−1.min−1 (−3.8, −0.9), p = 0.004; Oxygen uptake at Peak −4.0 ml.kg−1.min−1 (−6.8, −1.1), p = 0.011; and post-exercise phosphocreatine recovery rate constant −0.34 min−1 (−0.51, −0.17), p&lt;0.001. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="24" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="25" pm="."><plain>The significant decrease in both whole-body physical fitness and in vivo muscle mitochondrial function raises the possibility that muscle mitochondrial mechanisms, no doubt multifactorial, may be important in deterioration of physical fitness following neoadjuvant chemoradiotherapy. </plain></SENT>
<SENT sid="26" pm="."><plain>This may have implications for targeted interventions to improve physical fitness pre-surgery. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="27" pm="."><plain>Trial Registration </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="28" pm="."><plain>Clinicaltrials.gov registration <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01859442">NCT01859442</ext-link> </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>The research was funded in part from the British Oxygen Company Chair of the Royal College of Anaesthetists (MPWG), awarded by the National Institute of Academic Anaesthesia. Some of this work was undertaken at University Southampton NHS Foundation Trust - University of Southampton NIHR Respiratory Biomedical Research Unit which received a portion of funding from the UK Department of Health Research Biomedical Research Units funding scheme. All funding was unrestricted. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The authors confirm that all data underlying the findings are fully available without restriction. Data will be made available on Clinical trials.gov NCT01859442 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01859442">http://clinicaltrials.gov/show/NCT01859442</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The authors confirm that all data underlying the findings are fully available without restriction. Data will be made available on Clinical trials.gov NCT01859442 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01859442">http://clinicaltrials.gov/show/NCT01859442</ext-link>.</p></notes></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="29" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="30" pm="."><plain>In the UK colorectal cancer is the third commonest cause of cancer death [1], [2]. </plain></SENT>
<SENT sid="31" pm="."><plain>In 2013, ∼9000 patients were diagnosed with rectal cancer (35% aged &gt;75 y), of whom ∼4600 underwent major resection with a 90-day elective postoperative mortality of 2.5% [3]. </plain></SENT>
<SENT sid="32" pm="."><plain>25% are locally advanced (Tumour, Node, Metastasis (TNM) stage - T3/T4N+) cancers (i.e. resection margin threatened) considered for neoadjuvant chemoradiotherapy (NACRT) to control local disease and to achieve tumour downsizing and negative resection margins [4]–[8]; however, external beam radiation and oral or intravenous fluoropyrimidines causes dose-limiting toxicity, reaching Grade 3–5 in 20% (Common Terminology Criteria for Adverse Events, Version 3.0). </plain></SENT>
<SENT sid="33" pm="."><plain>It is unknown to what extent NACRT affects physical fitness in this patient cohort. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>Poor physical fitness, assessed by cardiopulmonary exercise testing (CPET), is linked to poor postoperative outcomes after major surgery [9]–[15]. </plain></SENT>
<SENT sid="35" pm="."><plain>CPET provides an integrated quantitative assessment of the cardiorespiratory system at rest and under the stress of maximal exercise, testing the physiological reserve required to withstand the stress of surgery. </plain></SENT>
<SENT sid="36" pm="."><plain>Subjective assessment tools have been used to predict surgical outcomes, but there is little evidence linking objectively-measured physical fitness and surgical outcome in this group. </plain></SENT>
<SENT sid="37" pm="."><plain>The UK National Bowel Cancer Audit found the American Society of Anaesthesiologists – Physical Status (ASA-PS) score (a categorical descriptor of fitness for surgery) to be the strongest predictor of death within 30 days of surgery [16]. </plain></SENT>
<SENT sid="38" pm="."><plain>Only two trials have suggested that rectal cancer patients with a higher subjective performance status (WHO Score &gt;1) have worse post-operative outcome after combined chemotherapy or chemo-radiation and surgery [17], [18]. </plain></SENT>
<SENT sid="39" pm="."><plain>Studies investigating objective changes in physical fitness in patients receiving neoadjuvant cancer treatments are lacking [19]. </plain></SENT>
<SENT sid="40" pm="."><plain>We have previously demonstrated a significant reduction in objectively measured physical fitness with neoadjuvant chemotherapy in upper gastrointestinal cancer which was associated with reduced 1 year survival [20] and a similar reduction in fitness with neoadjuvant chemoradiotherapy in rectal cancer which was associated with in-hospital morbidity [21]. </plain></SENT>
<SENT sid="41" pm="."><plain>Whether and how this impaired physical fitness relates to changes in mitochondrial function is unknown. </plain></SENT>
</text></p><p><text><SENT sid="42" pm="."><plain>Skeletal muscle mitochondrial function can be studied non-invasively in vivo using phosphorus magnetic resonance spectroscopy (31P MRS) [22]; this can usefully be combined with CPET measurements [23], [24] of whole-body fitness, to which muscle mitochondrial function makes a substantial contribution. </plain></SENT>
<SENT sid="43" pm="."><plain>Good correlations are observed between in vivo and in vitro measures of mitochondrial function in health and chronic conditions (e.g. type 2 diabetes) makes the assessment of mitochondrial function by 31P MRS an attractive and reliable modality, especially for repeated measurements [24]–[26]. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>The primary aim of this pilot study was to evaluate changes in objectively-measured physical fitness and skeletal muscle mitochondrial function after standardized NACRT, in patients scheduled for rectal cancer surgery. </plain></SENT>
<SENT sid="45" pm="."><plain>An exploratory aim was to observe changes in physical activity (PA) in the same patient cohort. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s2"><title><text><SENT sid="46" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="47" pm="."><plain>Patients and clinical methods </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>The protocol for this trial and supporting TREND checklist are available as supporting information; see Checklist S1 and Protocol S1. </plain></SENT>
<SENT sid="49" pm="."><plain>This nested mechanism pilot study forms part of a larger clinical trial which began in March 2011. </plain></SENT>
<SENT sid="50" pm="."><plain>Ethics approval for the main trial was given by the North West – Liverpool East Research and Ethics Committee (11/H1002/12) in March 2011, with a subsequent amendment (11/H1002/12c) adding 31P MRS measurements for this nested mechanism pilot sub-study approved in January 2012. </plain></SENT>
<SENT sid="51" pm="."><plain>The larger trial was registered with clinicaltrials.gov (NCT01325909 – March 2011), and initially this NCT registration was taken to cover all aspects of the larger trial, including the present pilot study. </plain></SENT>
<SENT sid="52" pm="."><plain>Subsequently the pilot study was registered separately (NCT 01859442 – May 2013), and as a result of this change of approach this specific registration post-dated the recruitment of the first patients reported here, for which studies commenced in October 2012. </plain></SENT>
<SENT sid="53" pm="."><plain>The authors confirm that all ongoing and related trials for this intervention are registered. </plain></SENT>
<SENT sid="54" pm="."><plain>Written informed consent was obtained from all patients. </plain></SENT>
<SENT sid="55" pm="."><plain>All patients were followed up until surgery, with the last patient exiting the study in October 2013. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>We recruited consecutive patients between October 2012 and July 2013 who were referred to the Colorectal Multi-Disciplinary Team (MDT), age ≥18 y, with locally advanced resectable rectal cancer (circumferential resection margin threatened), scheduled for standardized NACRT on the basis of Tumour, Node, Metastasis (TNM) classification &gt;T2/N+ with no distant metastasis [27] and WHO Performance Status &lt;2 [28]. </plain></SENT>
<SENT sid="57" pm="."><plain>Predefined exclusion criteria were: inability to give informed consent, non-resectable disease, standard MR exclusion criteria, inability to exercise studies due to leg dysfunction, and patients who declined surgery or NACRT, or who received non-standard NACRT. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>TNM staging involved flexible sigmoidoscopy for histological diagnosis, colonoscopy, chest, abdomen and pelvis computer-aided tomography (CT) and a 1.5T pelvic magnetic resonance imaging (MRI). </plain></SENT>
<SENT sid="59" pm="."><plain>All patients then underwent standardised NACRT for 5 weeks. </plain></SENT>
<SENT sid="60" pm="."><plain>Standardized radiotherapy consisted of 45 Gy in 25 fractions on weekdays using a 3-dimensional conformal technique with CT guidance. </plain></SENT>
<SENT sid="61" pm="."><plain>A boost dose was given (5.4 Gy in 3 fractions) to the primary tumour only. </plain></SENT>
<SENT sid="62" pm="."><plain>Oral capecitabine (825 mg.m−2) was given twice daily on radiotherapy days. </plain></SENT>
<SENT sid="63" pm="."><plain>No patients received brachytherapy. </plain></SENT>
<SENT sid="64" pm="."><plain>The colorectal multidisciplinary team (MDT) was blind to CPET results, which therefore did not influence perioperative management. </plain></SENT>
<SENT sid="65" pm="."><plain>All patients underwent total mesorectal excision (TME) surgery [29]. </plain></SENT>
<SENT sid="66" pm="."><plain>A defunctioning stoma was constructed at the discretion of the surgeon. </plain></SENT>
<SENT sid="67" pm="."><plain>No deviations from the protocol were encountered. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="68" pm="."><plain>CPET </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>CPET (Geratherm Respiratory GmbH; Love Medical Ltd, Manchester, United Kingdom) and the estimation of the estimated anaerobic threshold followed a standard protocol described in detail elsewhere [14]. </plain></SENT>
<SENT sid="70" pm="."><plain>Patient characteristics recorded included age, gender, height, weight, diagnosis, staging, surgical procedure planned, WHO classification, ASA-PS, and diagnoses of diabetes, ischaemic heart disease, cerebrovascular disease, or heart failure. </plain></SENT>
<SENT sid="71" pm="."><plain>Resting flow-volume loops were used to derive Forced Expiratory Volume over 1 second (FEV1) and Forced Vital Capacity (FVC). </plain></SENT>
<SENT sid="72" pm="."><plain>Ventilation and gas exchange variables included oxygen uptake (o2), ventilatory equivalents for oxygen and carbon dioxide ( E/o2;  E/co2) and oxygen pulse (o2/heart rate), all measured both at estimated anaerobic threshold ( L) and at peak exercise. </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>NACRT associated toxicity and CPET-related adverse events were discussed at the weekly MDT meeting. </plain></SENT>
<SENT sid="74" pm="."><plain>Toxicity events were graded on the National Cancer Institute Common Terminology Criteria (version 3.0), and acute radiation-induced skin toxicity using the Radiation Therapy Oncology Group scoring system. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="75" pm="."><plain>Physical activity </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>PA was measured during a continuous 72 h period using a biaxial accelerometer (SenseWear armband BodyMedia Inc., Pittsburgh, USA), worn over the right triceps during weekdays at baseline and post-NACRT. </plain></SENT>
<SENT sid="77" pm="."><plain>Step count while active averaged over the whole 72 h was used as a measure of PA. </plain></SENT>
<SENT sid="78" pm="."><plain>All patients were instructed not to change their PA, and to continue performing normal activities of daily living throughout the study period. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="79" pm="."><plain>MRS methods </plain></SENT>
</text></title><p><text><SENT sid="80" pm="."><plain>31P MRS assessments of muscle mitochondrial function in quadriceps were carried out using a Siemens 3T Trio MR scanner (Siemens AG, Erlangen, Germany) using an isometric knee extension exercise protocol. </plain></SENT>
<SENT sid="81" pm="."><plain>Subjects lay supine (secured with a Velcro strap across the hips) with the right knee flexed over a rigid foam support in a custom-built rig permitting isometric knee extension exercise against a strap across the anterior lower shin/ankle connected to an aluminium bar fitted with a strain gauge. 31P MRS data were acquired from right quadriceps muscle using a dual-tuned 18 cm/15 cm diameter 31P/1H surface coil (RAPID Biomedical, Rimpar, Germany), Velcro-strapped to the anterior thigh (midway between anterior superior iliac spine and patella). </plain></SENT>
<SENT sid="82" pm="."><plain>After automated set-up and manual shimming using tissue water signal, a 4-scan fully relaxed (TR = 10s) spectrum and a 32-scan partially saturated (TR = 2s) resting spectrum were collected. </plain></SENT>
<SENT sid="83" pm="."><plain>The exercise protocol consisted of 5 min rest followed by 2 bouts of isometric exercise (paced at 2 s on, 2 s off by an audible cue, exercise force being fed back visually via an LED display) each followed by 7 min recovery, while spectra were collected (TR = 2s) every 8 s. Two exercise intensities were used, corresponding to 70% and 90% of maximal voluntary contraction established in 3 brief trials prior to MRS acquisition (in pilot experiments these intensities gave acceptable PCr depletion with minimal acidification in typical subjects). </plain></SENT>
<SENT sid="85" pm="."><plain>Block MRS data output files from exercise-recovery acquisitions were converted to text using a specially-written MATLAB routine. </plain></SENT>
<SENT sid="86" pm="."><plain>All 31P MRS data were processed using the java-based Magnetic Resonance User Interface (jMRUI v.3.0), using the AMARES time-domain fitting algorithm. </plain></SENT>
<SENT sid="87" pm="."><plain>Data were fitted assuming Lorentzian lineshapes for phosphocreatine (PCr), inorganic phosphate (Pi) and ATP (β-ATP a 1∶2∶1 triplet, α-ATP and γ-ATP both 1∶1 doublets). </plain></SENT>
<SENT sid="88" pm="."><plain>The chemical shift of Pi relative to PCr was used by standard means to determine intracellular pH. </plain></SENT>
<SENT sid="89" pm="."><plain>PCr recovery time courses were fitted to a monoexponential function to estimate the recovery rate constant (kPCr min−1): in the absence of appreciable changes in pH, this is an accepted measure of effective muscle mitochondrial function. </plain></SENT>
<SENT sid="90" pm="."><plain>As kPCr did not differ significantly between the two exercise intensities, and as pH changes were small throughout, values of kPCr are presented as mean of the two intensities [30]. </plain></SENT>
</text></p><p><text><SENT sid="91" pm="."><plain>All patients underwent CPET, PA monitoring and 31P MRS 2 weeks before NACRT (baseline) and immediately post-NACRT (post-NACRT) that is within 48 hours of finishing NACRT. </plain></SENT>
<SENT sid="92" pm="."><plain>CPET data were reported by two experienced assessors blind to patient demographics and data time-points. </plain></SENT>
<SENT sid="93" pm="."><plain>Any CPET or exercise-related adverse events were discussed at the weekly colorectal MDT meeting. 31P MRS analysis was performed blind to clinical details and CPET data. </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>Our primary outcome variables include o2 at  L, o2 Peak and kPCr, assessed with CPET and 31P MRS; an exploratory outcome variable is the number of steps whilst active, assessed by PA monitoring. </plain></SENT>
<SENT sid="95" pm="."><plain>A comparison of these variables is made between baseline and post-NACRT. </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="96" pm="."><plain>Statistical methods </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>Our aim was to recruit 12 patients to a pilot study who would undergo standardised NACRT, CPET and 31P MRS scans at baseline (pre-NACRT) and immediately post-NACRT. </plain></SENT>
<SENT sid="98" pm="."><plain>No formal sample size calculation was performed as this study was designed as a nested pilot study: the target number was based on experience and reports of similar clinical 31P MRS studies and pragmatic considerations of recruitment logistics and funding. </plain></SENT>
<SENT sid="99" pm="."><plain>Descriptive statistics are reported as mean (SD) or median and inter-quartile range (IQR) depending on the distribution and categorical statistics as frequency (percentage). </plain></SENT>
<SENT sid="100" pm="."><plain>Normality was assessed by the Shapiro-Wilk test. </plain></SENT>
<SENT sid="101" pm="."><plain>Pre- and post-NACRT data were compared using paired t-tests. </plain></SENT>
</text></p><p><text><SENT sid="102" pm="."><plain>For the primary analysis, baseline and post-NACRT measurements for o2 at  L, o2 Peak and kPCr were compared using a paired t-test as an intention to treat. </plain></SENT>
<SENT sid="103" pm="."><plain>Formal comparisons were considered to be statistically significant at p&lt;0.05. </plain></SENT>
<SENT sid="104" pm="."><plain>Spearman's correlation coefficient (r) was used to describe the strength of association between changes in o2 at  L and change in haemoglobin. </plain></SENT>
<SENT sid="105" pm="."><plain>For PA these comparisons were considered as exploratory and tested against the uncorrected 5% significance level; the need to square-root transform PA makes it impossible to recover the differences and confidence intervals on a meaningful scale, so only p-values and predicted means are presented. </plain></SENT>
<SENT sid="106" pm="."><plain>These analyses were conducted using Stata version 12 (StataCorp. </plain></SENT>
<SENT sid="107" pm="."><plain>2011. Stata Statistical Software: Release 12. </plain></SENT>
<SENT sid="108" pm="."><plain>College Station, TX: StataCorp LP.) </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="109" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="110" pm="."><plain>Patient flow and characteristics </plain></SENT>
</text></title><p><text><SENT sid="111" pm="."><plain>Fifteen patients were eligible for surgery, of which 3 were recruited into a different trial; 12 patients (10 males and 2 females) were recruited and underwent CPET and 31P MRS prior to starting a standardised course of NACRT (Figure 1). </plain></SENT>
<SENT sid="112" pm="."><plain>All CPETs were carried out 48±5 hours before the 31P MRS scan both at baseline and post-NACRT. </plain></SENT>
<SENT sid="113" pm="."><plain>All patients underwent CPET and 31P MRS immediately after (post-NACRT) finishing NACRT (at a maximum of 48±5 hours). Table 1 describes baseline patient characteristics and Table 2 describes patient characteristics between baseline and post-NACRT. </plain></SENT>
<SENT sid="114" pm="."><plain>There were no significant changes in BMI or lung function following NACRT, but there was a small but significant fall in haemoglobin. </plain></SENT>
<SENT sid="115" pm="."><plain>83% of diagnosed rectal cancers were T3 with threatened circumferential resection margins. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0111526-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111526.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="116" pm="."><plain>Showing flow of patients through the study protocol. </plain></SENT>
</text></title><p><text><SENT sid="117" pm="."><plain>Post-NACRT tests carried out within 48±5 hours of finishing NACRT period. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0111526.g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone-0111526-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111526.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="118" pm="."><plain>Baseline patient characteristics. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0111526-t001-1" xlink:href="pone.0111526.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Mean (SD) </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>69 (10) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>Number (%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>Gender Male:Female </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>10 (83): 2 (17) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>Currently smoking </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>2 (17) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>Past medical history </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>Diabetes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>1 (8) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Ischaemic heart disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>2 (17) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>Heart failure &amp; cerebrovascular disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>American Society of Anaesthesiologists (ASA) score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>6 (50) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>6 (50) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>World Health Organisation performance status </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>9 (75) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>3 (25) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>Tumour distance from anal verge (cm) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>&lt;5.0 cm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>6 (50) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>5.1–10.0 cm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>5 (42) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>&gt;10.1 cm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>1 (8) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>International Union against Cancer Tumour Node Metastasis (TNM) MRI staging </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>cT3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>10 (83) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>cT4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>2 (17) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>cN0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>3 (33) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>cN1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>4 (17) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>cN2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>5 (50) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>cM0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>12 (100) </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="pone-0111526-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111526.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="164" pm="."><plain>Patient characteristics at Baseline and post-NACRT. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0111526-t002-2" xlink:href="pone.0111526.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>Baseline </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>Post-NACRT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>Mean difference </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>P </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>mean (SD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>mean (SD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>(95% CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>BMI (kg.m−2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>26.8 (3.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>26.3 (3.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>−0.5 (−0.5, 1.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>0.291 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>FEV1 (l) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>3.0 (0.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>2.9 (0.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>−0.1 (−0.1, 0.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>0.153 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>FVC (l) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>4.3 (0.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>4.2 (0.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>−0.2 (−0.1, 0.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>0.188 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>FEV1/FVC (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>72 (7.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>73 (7.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>1.2 (−3.1, 0.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>0.215 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>Haemoglobin (g.dl−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>13.2 (1.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>12.9 (1.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>−0.4 (0.5, 0.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>0.034 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="s3b"><title><text><SENT sid="197" pm="."><plain>Chemoradiotherapy and acute toxicity </plain></SENT>
</text></title><p><text><SENT sid="198" pm="."><plain>The mean cumulative dose of capecitabine was 96% (range 84–100%) of the planned treatment dose; 1 patient needed dose reduction. </plain></SENT>
<SENT sid="199" pm="."><plain>All but 1 patient received at least 45 Gy radiotherapy, and all completed the full 25 fractions. </plain></SENT>
<SENT sid="200" pm="."><plain>2 patients (including 1 receiving a diverting stoma because of obstructive symptoms prior to NACRT) experienced grade 3 toxicity, notably diarrhoea and radiation dermatitis, but no grade 4 toxicity was reported. </plain></SENT>
</text></p></sec><sec id="s3c"><title><text><SENT sid="201" pm="."><plain>The effect of NACRT on physical fitness, physical activity and mitochondrial function </plain></SENT>
</text></title><p><text><SENT sid="202" pm="."><plain>Table 3 shows CPET, PA and 31P MRS-derived variables pre- and post-NACRT. </plain></SENT>
<SENT sid="203" pm="."><plain>No exercise or MRS adverse events were encountered until end of follow-up. </plain></SENT>
<SENT sid="204" pm="."><plain>Post-NACRT, there were significant decreases in both absolute (ml.min−1) and relative (ml.kg−1.min−1) o2, in O2 pulse at  L and at Peak exercise, in baseline heart rate, in kPCr and in the number of steps (although this is strongly influenced by an apparent outlier; difference in the number of steps was not significant after the outlier was removed); Figure 2 shows mean and individual values of kPCr, o2 at  L and o2 at Peak, while Figure 3 shows the mean number of daily steps.  E/co2 and work rates at  L and Peak exercise did not change. </plain></SENT>
<SENT sid="205" pm="."><plain>No significant relationship was found between the change in o2 at  L and change in haemoglobin (r = 0.27; p = 0.396). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0111526-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111526.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="206" pm="."><plain>31P MRS (kPCr) and CPET (o2 at  L and o2 at Peak) data at Baseline (before NACRT)) and at 48±5 hours post-NACRT: lines link data-points (closed circles) for individual patients, and open circles show overall mean±SEM. </plain></SENT>
<SENT sid="207" pm="."><plain>Mean changes (SEM) between baseline and post-NACRT are for kPCr −0.4(0.1) min−1, p = 0.001; for o2 at  L −2.4(0.7) ml.kg−1.min−1, p = 0.004; and for o2 Peak −4.0(1.3) ml.kg−1.min−1, p = 0.011. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0111526.g002"/></fig></SecTag><SecTag type="FIG"><fig id="pone-0111526-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111526.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="208" pm="."><plain>Averaged number of steps at Baseline (before NACRT)) and at 48±5 hours post-NACRT: lines link data-points (closed circles) for individual patients, and open circles show overall mean±SEM. </plain></SENT>
<SENT sid="209" pm="."><plain>Mean change (SEM) between baseline and post-NACRT is −1627(712) steps, p = 0.039. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0111526.g003"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone-0111526-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111526.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="210" pm="."><plain>Patient data at Baseline and post-NACRT. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0111526-t003-3" xlink:href="pone.0111526.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>Baseline </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>Post-NACRT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>Mean difference </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>P </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>mean (SD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>mean (SD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>(95% CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>kPCr 1 (min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>1.5 (0.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>1.1 (0.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>−0.4 (−0.5, −0.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>o2 at  L (ml.kg−1.min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>12.3 (3.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>9.9 (2.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>−2.4 (−3.8, −0.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>0.004 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>o2 at  L (L.min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>0.9 (0.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>0.7 (0.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>−0.2 (−0.1, −0.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>0.003 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>o2 Peak (ml.kg−1.min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>18.7 (6.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>14.7 (4.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>−4.0 (−6.8, −1.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0.011 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>o2 Peak (L.min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>1.4 (0.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>1.1 (0.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>−0.3 (−0.1, −0.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>0.013 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>O2 pulse at  L (ml.beat−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>8.9 (2.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>7.7 (2.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>−1.2 (−0.2, −2.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>0.022 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>O2 pulse at Peak (ml.beat−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>10.5 (3.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>8.7 (2.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>−1.8 (−0.3, −3.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>0.024 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain> E/co2 at  L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>34.5 (6.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>34.2 (4.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>−0.3 (2.5, −3.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>0.825 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain> E/co2 at Peak </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>35.9 (4.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>37.1 (4.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>0.3 (−3.7, 1.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>0.080 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>Average number of steps </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>5352 (3913) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>3725 (2217) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>−1627 (−59, 3195) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>0.039 </plain></SENT>
</text></td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>median (IQR) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>median (IQR) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>(95% CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>Baseline heart rate (beats.min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>76 (71, 90) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>68 (61, 81) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>−7 (−1.0, −13.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>0.028 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Peak heart rate (beats.min−1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>135 (126, 142) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>130 (115, 143) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>−5 (−4.1, 14.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>0.235 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Work rate at  L (W) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>55 (39,77) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>56 (39,73) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>1 (−8.4, 9.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>0.904 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Work rate at Peak (W) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>109 (71,134) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>113 (79,128) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>4 (−12.2,24.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>0.475 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p><text><SENT sid="291" pm="."><plain>Abbreviations: kPCr, post-exercise phosphocreatine recovery rate constant; o2 at  L, oxygen uptake at estimated anaerobic threshold; o2 Peak, oxygen uptake at peak exercise; O2 pulse at  L, oxygen pulse at estimated anaerobic threshold; O2 pulse at Peak, oxygen pulse at peak exercise;  E/co2 at  L, ventilatory equivalents for carbon dioxide at estimated anaerobic threshold;  E/co2 at  L, ventilatory equivalents for carbon dioxide at peak exercise; Work rate at  L, work rate at estimated anaerobic threshold; Work rate at Peak, work rate at peak exercise. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="292" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="293" pm="."><plain>This is the first study to identify mitochondrial abnormalities accompanying changes in physical fitness following neoadjuvant chemoradiotherapy. </plain></SENT>
<SENT sid="294" pm="."><plain>The benefits of NACRT for locally advanced rectal cancer are improved local disease control and possibly overall and cancer-specific survival; however its effect on objectively measured physical fitness has not been measured, nor has the mechanism of this been explored in vivo. </plain></SENT>
</text></p><p><text><SENT sid="295" pm="."><plain>This pilot study shows a significant reduction in both whole-body physical fitness measured by CPET (o2 at  L −2.36 ml.kg−1.min−1, o2 at Peak −3.95 ml.kg−1.min−1) and in vivo muscle mitochondrial function kPCr (−0.34 min−1) between baseline and post-NACRT. </plain></SENT>
<SENT sid="296" pm="."><plain>We also found a significant decline in PA with NACRT (−1627 steps). </plain></SENT>
<SENT sid="297" pm="."><plain>This acute decline in mitochondrial function may account for the rapid loss in fitness and activity over the neoadjuvant treatment period, clinically important in the context of fitness for surgery and perioperative risk however causality cannot be established as controlling for PA in a clinical setting is difficult, and statistical adjustment for PA in a small patient group is not feasible. </plain></SENT>
<SENT sid="298" pm="."><plain>These findings however illuminate a potential mechanistic link that might be contributing to the changes in objectively measured whole body physical fitness with NACRT, consistent with the results of our earlier pilot study [21]. </plain></SENT>
</text></p><p><text><SENT sid="299" pm="."><plain>Cancer-induced cachexia can cause major loss of skeletal muscle, resulting in fatigue and higher mortality [31],[32]. </plain></SENT>
<SENT sid="300" pm="."><plain>In our cohort cancer progression is not a contributing factor as tumours were downstaged. </plain></SENT>
<SENT sid="301" pm="."><plain>Furthermore BMI and weight remained stable. </plain></SENT>
<SENT sid="302" pm="."><plain>The small but statistically significant fall in haemoglobin is unlikely to be functionally relevant, and showed no correlation with the CPET or 31P MRS changes. </plain></SENT>
</text></p><p><text><SENT sid="303" pm="."><plain>Several publications postulate mechanisms by which chemotherapy may contribute to skeletal muscle dysfunction [33]. </plain></SENT>
<SENT sid="304" pm="."><plain>Oxidative damage [34] resulting from doxorubicin-based chemotherapy in haematological malignancies causes sarcopaenia [35], up-regulation of E3 ubiquitin-ligase/MAFbx [35] and mitochondrial death [36]. </plain></SENT>
<SENT sid="305" pm="."><plain>Drugs with a quinone moiety can directly interact with oxygen to generate reactive oxygen species (ROS) causing oxidative stress-mediated injury to cardiac muscle, kidneys and brain tissue [37], while other chemotherapeutic agents decrease antioxidant levels [37]; however these chemotherapy regimens were not used in this cohort. </plain></SENT>
<SENT sid="306" pm="."><plain>At subcellular levels, mitochondria are major targets for chemotherapy-induced oxidative stress [36]. </plain></SENT>
<SENT sid="307" pm="."><plain>Chemotherapy is known to affect cardiorespiratory (causing exercise intolerance) [38] and microcirculatory function [39], PA [33], but these multifactorial physiological mechanisms remain elusive. </plain></SENT>
</text></p><p><text><SENT sid="308" pm="."><plain>Mitochondrial function measured by 31P MRS is impaired in a variety of chronic diseases, as well as primary mitochondrial disease. </plain></SENT>
<SENT sid="309" pm="."><plain>In peripheral arterial occlusive disease [30], [40] this mainly reflects impaired O2 delivery to the muscle. </plain></SENT>
<SENT sid="310" pm="."><plain>In cardiac failure [41] and COPD [42], [43] it is likely to reflect a multifactorial pathology including reduced PA, mitochondrial density [44] and ROS mechanisms. </plain></SENT>
<SENT sid="311" pm="."><plain>Similar mechanisms might mediate the decline in physical fitness in our cohort. </plain></SENT>
<SENT sid="312" pm="."><plain>The acute decline in PA seen might also contribute to changes in mitochondrial function and physical fitness. </plain></SENT>
<SENT sid="313" pm="."><plain>A better understanding and quantification of the potential mechanisms involved if oxidative injury is present in this patient cohort is essential to design intervention strategies that will attenuate the toxicity of chemoradiotherapy agents without compromising their anticancer effects [36] </plain></SENT>
</text></p><p><text><SENT sid="314" pm="."><plain>Our findings have potential clinical implications because reduced physical fitness is associated with increased perioperative morbidity and mortality after major intra-abdominal surgery, especially colorectal surgery [14], [15], [45] Our data provides the first direct evidence that the benefits of NACRT in tumour downsizing may be at least partly offset by increased perioperative risk as a result of reduced physical fitness, related to reduced skeletal muscle mitochondrial function and activity however causality cannot be established. </plain></SENT>
<SENT sid="315" pm="."><plain>This proposed mechanism merits further investigation, as does the possibility of preventive interventions e.g. by exercise training during the pre-operative period (currently the focus of our published exercise training study [46]). </plain></SENT>
<SENT sid="316" pm="."><plain>This is an interventional pilot study in the same patient cohort scheduled to undergo standardised NACRT and a 6-week structured, tailored exercise training programme (exercise group n = 22) or a control period (n = 13). </plain></SENT>
<SENT sid="317" pm="."><plain>Here o2 at  L significantly reduced between baseline and post-NACRT (−1.9 ml.kg−1.min−1). </plain></SENT>
<SENT sid="318" pm="."><plain>In the exercise group o2 at  L significantly improved between post-NACRT and week 6 post-NACRT (+2.1 ml.kg−1.min−1) whereas control group values were unchanged (−0.7 ml.kg−1.min−1). </plain></SENT>
<SENT sid="319" pm="."><plain>Furthermore a randomised controlled study investigating the potential benefits in physical fitness and quality of life of a 9-week structured responsive endurance training programme following NACRT prior to elective rectal cancer surgery (PB-PG-0711-25093) is currently recruiting. </plain></SENT>
</text></p><p><text><SENT sid="320" pm="."><plain>This study demonstrates an acute decline in objectively-measured physical fitness, activity as well as a decline in mitochondrial function using validated and robust methodology. </plain></SENT>
<SENT sid="321" pm="."><plain>Particular strengths of our study are the low risk of confounding by indication [47], the blinded physiological evaluations, the standardization of the NACRT and the homogenous cancer cohort. </plain></SENT>
<SENT sid="322" pm="."><plain>Limitations lie in the observational design, the small sample size of what was designed as a pilot study and that no adjusting for multiple testing was performed. </plain></SENT>
</text></p><p><text><SENT sid="323" pm="."><plain>In conclusion, NACRT before major rectal cancer surgery significantly reduces physical fitness objectively assessed by CPET and muscle mitochondrial function assessed by 31P MRS. </plain></SENT>
<SENT sid="324" pm="."><plain>The existence of abnormalities at both skeletal-muscle and whole-body level may perhaps suggest a potential mechanistic relationship in NACRT which merits further investigation, which could potentially inform development of tailored interventions in the perioperative period to improve both physical fitness and mitochondrial function in patients with operable rectal cancer. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="325" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0111526.s001"><label>Checklist S1</label><caption><p><text><SENT sid="326" pm="."><plain>TREND statement checklist. </plain></SENT>
</text></p><p><text><SENT sid="327" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0111526.s001.pdf"><caption><p><text><SENT sid="328" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0111526.s002"><label>Protocol S1</label><caption><p><text><SENT sid="329" pm="."><plain>Study protocol for patients consented to this trial. </plain></SENT>
</text></p><p><text><SENT sid="330" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0111526.s002.docx"><caption><p><text><SENT sid="331" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="332" pm="."><plain>Aintree University Hospitals Colorectal Multi Disciplinary Team; Institute of Ageing and Chronic Disease, University of Liverpool; University Southampton NHS Foundation Trust - University of Southampton NIHR Respiratory Biomedical Research Unit. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0111526-Statistical1"><text><SENT sid="333" pm="."><plain>1Statistical Bulletin Cancer registrations in England (2010), 1–11. </plain></SENT>
<SENT sid="334" pm="."><plain>Available: <ext-link ext-link-type="uri" xlink:href="http://www.ons.gov.uk/ons/search/index.html?newquery=cancer+registrations">http://www.ons.gov.uk/ons/search/index.html?newquery=cancer+registrations</ext-link>. </plain></SENT>
<SENT sid="335" pm="."><plain>Accessed 03/03/2014 </plain></SENT>
</text></ref><ref id="pone.0111526-Statistical2"><text><SENT sid="336" pm="."><plain>2Statistical Bulletin Cancer Incidence and Mortality in the United Kingdom, 2008-10 (2012), 1–24. </plain></SENT>
<SENT sid="337" pm="."><plain>Available <ext-link ext-link-type="uri" xlink:href="http://www.ons.gov.uk/ons/search/index.html?newquery=cancer+registrations">http://www.ons.gov.uk/ons/search/index.html?newquery=cancer+registrations</ext-link>. </plain></SENT>
<SENT sid="338" pm="."><plain>Accessed 03/03/2014 </plain></SENT>
</text></ref><ref id="pone.0111526-Association1"><text><SENT sid="339" pm="."><plain>3Association of Coloproctology of Great Britain and Ireland. </plain></SENT>
<SENT sid="340" pm="."><plain>National Bowel Cancer Audit Annual Report (2013) Available: <ext-link ext-link-type="uri" xlink:href="http://www.acpgbi.org.uk/content/uploads/Bowel-Cancer-Audit-2013_INTERACTIVE-PDF_01-07-13.pdf">http://www.acpgbi.org.uk/content/uploads/Bowel-Cancer-Audit-2013_INTERACTIVE-PDF_01-07-13.pdf</ext-link>. </plain></SENT>
<SENT sid="341" pm="."><plain>Accessed 03/03/2014 </plain></SENT>
</text></ref><ref id="pone.0111526-HabrGama1"><text><SENT sid="342" pm="."><plain>4 Habr-GamaA, PerezRO, NadalinW, SabbagaJ, RibeiroU, et al (2004) Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy. Ann Surg 240(4):711–718.15383798 </plain></SENT>
</text></ref><ref id="pone.0111526-Chau1"><text><SENT sid="343" pm="."><plain>5 ChauI, BrownG, CunninghamD, TaitD, WotherspoonA, et al (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24(4):668–674.16446339 </plain></SENT>
</text></ref><ref id="pone.0111526-Mohiuddin1"><text><SENT sid="344" pm="."><plain>6 MohiuddinM, WinterK, MitchellE, HannaN, YuenA, et al (2006) Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24(4):650–655.16446336 </plain></SENT>
</text></ref><ref id="pone.0111526-Bosset1"><text><SENT sid="345" pm="."><plain>7 BossetJF, ColletteL, CalaisG, MineurL, MaingonP, et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123.16971718 </plain></SENT>
</text></ref><ref id="pone.0111526-Grard1"><text><SENT sid="346" pm="."><plain>8 GérardJP, ConroyT, BonnetainF, BouchéO, ChapetO, et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625.17008704 </plain></SENT>
</text></ref><ref id="pone.0111526-Lai1"><text><SENT sid="347" pm="."><plain>9 LaiCW, MintoG, ChallandCP, HosieKB, SneydJR, et al (2013) Patients' inability to perform a preoperative cardiopulmonary exercise test or demonstrate an anaerobic threshold is associated with inferior outcomes after major colorectal surgery. Br J Anaesth 111(4):607–611.23744818 </plain></SENT>
</text></ref><ref id="pone.0111526-Wilson1"><text><SENT sid="348" pm="."><plain>10 WilsonRJT, DaviesS, YatesD, RedmanJ, StoneM (2010) Impaired functional capacity is associated with all-cause mortality after major elective intra-abdominal surgery. Br J Anaesth 105(3):297–303.20573634 </plain></SENT>
</text></ref><ref id="pone.0111526-Snowden1"><text><SENT sid="349" pm="."><plain>11 SnowdenCP, PrentisJ, JacquesB, AndersonH, ManasD, et al (2013) Cardiorespiratory fitness predicts mortality and hospital length of stay after major elective surgery in older people. Ann Surg 257(6):999–1004.23665968 </plain></SENT>
</text></ref><ref id="pone.0111526-West1"><text><SENT sid="350" pm="."><plain>12 WestM, JackS, GrocottMPW (2011) Perioperative cardiopulmonary exercise testing in the elderly. Best Pract Res Clin Anaesthesiol 25(3):427–437.21925407 </plain></SENT>
</text></ref><ref id="pone.0111526-Carlisle1"><text><SENT sid="351" pm="."><plain>13 CarlisleJ, SwartM (2007) Mid-term survival after abdominal aortic aneurysm surgery predicted by cardiopulmonary exercise testing. Br J Surg 94(8):966–969.17440956 </plain></SENT>
</text></ref><ref id="pone.0111526-West2"><text><SENT sid="352" pm="."><plain>14 WestMA, LythgoeD, BarbenCP, NobleL, KempGJ, et al (2014) Cardiopulmonary exercise variables are associated with postoperative morbidity after major colonic surgery: a prospective blinded observational study. Br J Anaesth 112(4):665–671.24322573 </plain></SENT>
</text></ref><ref id="pone.0111526-Hennis1"><text><SENT sid="353" pm="."><plain>15 HennisPJ, MealePM, GrocottMPW (2011) Cardiopulmonary exercise testing for the evaluation of perioperative risk in non-cardiopulmonary surgery. Postgr Med J 87(1030):550–557. </plain></SENT>
</text></ref><ref id="pone.0111526-Finan1"><text><SENT sid="354" pm="."><plain>16 FinanP, GreenawayK (2012) Association of Coloproctology of Great Britain and Ireland. National Bowel Cancer Audit Annual Report 47–59. </plain></SENT>
</text></ref><ref id="pone.0111526-Swellengrebel1"><text><SENT sid="355" pm="."><plain>17 SwellengrebelHAM, MarijnenCAM, VerwaalVJ, VincentA, HeuffG, et al (2011) Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 98(3):418–26.21254020 </plain></SENT>
</text></ref><ref id="pone.0111526-Marijen1"><text><SENT sid="356" pm="."><plain>18 MarijenC, KapiteijnE, vab de VeldeC, MartijnH (2002) Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a mulitcenter randomized trial. J Clin Oncol 20(3):817–25.11821466 </plain></SENT>
</text></ref><ref id="pone.0111526-Jones1"><text><SENT sid="357" pm="."><plain>19 JonesLW, EvesND, HaykowskyM, JoyAA, DouglasPS (2008) Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol 9(8):757–65.18672211 </plain></SENT>
</text></ref><ref id="pone.0111526-Jack1"><text><SENT sid="358" pm="."><plain>20 JackS, WestM, RawD, MarwoodS, AmblerG, et al (2014) The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. Eur J Surg Oncol doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejso.2014.03.010(inpress)">10.1016/j.ejso.2014.03.010 (in press)</ext-link>  </plain></SENT>
</text></ref><ref id="pone.0111526-West3"><text><SENT sid="359" pm="."><plain>21 WestM, LoughneyL, BarbenC, SripadamR, KempG, et al (2014) The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients. Eur J Surg Oncol doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejso.2014.03.021(inpress)">10.1016/j.ejso.2014.03.021 (in press)</ext-link>  </plain></SENT>
</text></ref><ref id="pone.0111526-Kemp1"><text><SENT sid="360" pm="."><plain>22 KempGJ, BrindleKM (2012) What do magnetic resonance-based measurements of Pi→ATP flux tell us about skeletal muscle metabolism? Diabetes 61(8):1927–1934.22826313 </plain></SENT>
</text></ref><ref id="pone.0111526-Cannon1"><text><SENT sid="361" pm="."><plain>23 CannonDT, HoweFA, WhippBJ, WardSA, McIntyreDJ, et al (2013) Muscle metabolism and activation heterogeneity by combined 31P chemical shift and T2 imaging, and pulmonary O2 uptake during incremental knee-extensor exercise. J Appl Physiol 115(6):839–849.23813534 </plain></SENT>
</text></ref><ref id="pone.0111526-Praet1"><text><SENT sid="362" pm="."><plain>24 PraetSFE, De FeyterHMM, JonkersRAM, NicolayK, van PulC, et al (2006) 31P MR spectroscopy and in vitro markers of oxidative capacity in type 2 diabetes patients. Magn Reson Mater Phy 19(6):321–331. </plain></SENT>
</text></ref><ref id="pone.0111526-LarsonMeyer1"><text><SENT sid="363" pm="."><plain>25 Larson-MeyerD, NewcomerB, HunterG, JoanisseD, WeinsierRL, et al (2001) Relationship between in vivo and in vitro measurements of skeletal musle oxidative metabolism. Muscle Nerve 24:1665–1676.11745976 </plain></SENT>
</text></ref><ref id="pone.0111526-McCully1"><text><SENT sid="364" pm="."><plain>26 McCullyKK, TurnerTN, LangleyJ, ZhaoQ (2009) The reproducibility of measurements of intramuscular magnesium concentrations and muscle oxidative capacity using 31P MRS. Dyn Med 8(5):1–7.19144121 </plain></SENT>
</text></ref><ref id="pone.0111526-Sobin1"><text><SENT sid="365" pm="."><plain>27 SobinLH, FlemingID (1997) TNM Classification of Malignant Tumors,. Fifth Edition Cancer. 80(9):1803–1804.9351551 </plain></SENT>
</text></ref><ref id="pone.0111526-Oken1"><text><SENT sid="366" pm="."><plain>28 OkenMM, CreechRH, TormeyDC, HortonJ, DavisTE, et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655.7165009 </plain></SENT>
</text></ref><ref id="pone.0111526-MacFarlane1"><text><SENT sid="367" pm="."><plain>29 MacFarlaneJK, RyallRDH, HealdRJ (1993) Mesorectal excision for rectal cancer. Lancet 20 341(8843):457–60. </plain></SENT>
</text></ref><ref id="pone.0111526-Kemp2"><text><SENT sid="368" pm="."><plain>30 KempGJ, RobertsN, BimsonWE, BakranA, HarrisPL, et al (2001) Mitochondrial function and oxygen supply in normal and in chronically ischemic muscle: a combined 31P magnetic resonance spectroscopy and near infrared spectroscopy study in vivo. J Vasc Surg 34(6):1103–1110.11743568 </plain></SENT>
</text></ref><ref id="pone.0111526-Tisdale1"><text><SENT sid="369" pm="."><plain>31 TisdaleMJ (2001) Cancer anorexia and cachexia. Nutrition 17(5):438–442.11377146 </plain></SENT>
</text></ref><ref id="pone.0111526-Gilliam1"><text><SENT sid="370" pm="."><plain>32 GilliamLAA, St ClairDK, ClairDKS (2011) Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress. Antioxid Redox Signal 15(9):2543–2546.21457105 </plain></SENT>
</text></ref><ref id="pone.0111526-Powers1"><text><SENT sid="371" pm="."><plain>33 PowersSK, JacksonMJ (2010) Exercise-induced oxidative stress: Cellular mechanisms and impact on muscle force production. Physiol Rev 88(4):1243–1276. </plain></SENT>
</text></ref><ref id="pone.0111526-Tozer1"><text><SENT sid="372" pm="."><plain>34 TozerRG, TaiP, FalconerW, DucruetT, KarabadjianA, et al (2008) Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid Redox Signal 10(2):395–402.18158761 </plain></SENT>
</text></ref><ref id="pone.0111526-Yamamoto1"><text><SENT sid="373" pm="."><plain>35 YamamotoY, HoshinoY, ItoT, NariaiT, MohriT, et al (2008) Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79(1):89–96.18346979 </plain></SENT>
</text></ref><ref id="pone.0111526-Chen1"><text><SENT sid="374" pm="."><plain>36 ChenY, JungsuwadeeP, VoreM, ButterfieldD, St ClairD (2007) Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Mol Interv 7:147–156.17609521 </plain></SENT>
</text></ref><ref id="pone.0111526-Ladas1"><text><SENT sid="375" pm="."><plain>37 LadasEJ, JacobsonJS, KennedyDD, TeelK, FleischauerA, et al (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22(3):517–528.14752075 </plain></SENT>
</text></ref><ref id="pone.0111526-Jones2"><text><SENT sid="376" pm="."><plain>38 JonesLW, EvesND, HaykowskyM, FreedlandSJ, MackeyJR (2009) Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 10(6):598–605.19482248 </plain></SENT>
</text></ref><ref id="pone.0111526-Karvunidis1"><text><SENT sid="377" pm="."><plain>39 KarvunidisT, ChvojkaJ, LysakD, SykoraR, KrouzeckyA, et al (2012) Septic shock and chemotherapy-induced cytopenia: effects on microcirculation. Intensive Care Med 38(8):1336–1344.22584795 </plain></SENT>
</text></ref><ref id="pone.0111526-Pipinos1"><text><SENT sid="378" pm="."><plain>40 PipinosII, ShepardAD, AnagnostopoulosPV, KatsamourisA, BoskaMD (2000) Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle. J Vasc Surg 31(5):944–952.10805885 </plain></SENT>
</text></ref><ref id="pone.0111526-Massie1"><text><SENT sid="379" pm="."><plain>41 MassieBM, ConwayM, YongeR, FrostickS, SleightP, et al (1987) 31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol 60(4):309–315.3618489 </plain></SENT>
</text></ref><ref id="pone.0111526-PuenteMaestu1"><text><SENT sid="380" pm="."><plain>42 Puente-MaestuL, LázaroA, HumanesB (2013) Metabolic derangements in COPD muscle dysfunction. J Appl Physiol 114(9):1282–1290.23288549 </plain></SENT>
</text></ref><ref id="pone.0111526-PuenteMaestu2"><text><SENT sid="381" pm="."><plain>43 Puente-MaestuL, TejedorA, LázaroA, de MiguelJ, Alvarez-SalaL, et al (2012) Site of mitochondrial reactive oxygen species production in skeletal muscle of chronic obstructive pulmonary disease and its relationship with exercise oxidative stress. Am J Respir Cell Mol Biol 47(3):358–362.22493009 </plain></SENT>
</text></ref><ref id="pone.0111526-Gosker1"><text><SENT sid="382" pm="."><plain>44 GoskerHR, HesselinkMKC, DuimelH, WardKA, ScholsMWJ (2007) Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J 30(1):73–79.17428811 </plain></SENT>
</text></ref><ref id="pone.0111526-West4"><text><SENT sid="383" pm="."><plain>45 WestMA, ParryM, LythgoeD, BarbenC, KempG, et al (2014) Cardiopulmonary exercise variables are associated with postoperative morbidity after rectal cancer surgery. Br J Surg 101(9):1166–72.24916313 </plain></SENT>
</text></ref><ref id="pone.0111526-West5"><text><SENT sid="384" pm="."><plain>46 WestM, LoughneyL, LythgoeD, BarbenC, SripadamR, et al (2014) The effect of prehabilitation on objectively measured physical fitness following neoadjuvant treatment in preoperative rectal cancer patients – a blinded interventional pilot study. Br J Anaesth. in press. </plain></SENT>
</text></ref><ref id="pone.0111526-Grocott1"><text><SENT sid="385" pm="."><plain>47 GrocottMPW, PearseRM (2010) Prognostic studies of perioperative risk: robust methodology is needed. Br J Anaesth 105(3):243–245.20716567 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
